PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2015.40120164841177-1186East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL)Keunchil Park, Joo-Hang Kim, Eun Kyung Cho, Jin-Hyoung Kang, Jin-Yuan Shih, Annamaria Hayden Zimmermann, Pablo Lee, Ekaterine Alexandris, Tarun Puri, Mauro Orlandohttp://e-crt.org/upload/pdf/crt-2015-401.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2015.401, http://www.e-crt.org/upload/pdf/crt-2015-401.pdf
Clinical Lung Cancer10.1016/j.cllc.2012.06.0072012136505-509A Randomized, Double-Blind, Phase III Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non–Small-Cell Lung Cancer After Disease Progression After 1 Previous Platinum-Based Therapy (REVEL): Treatment Rationale and Study DesignEdward B. Garon, Dachuang Cao, Ekaterine Alexandris, William J. John, Sergey Yurasov, Maurice Perolhttps://api.elsevier.com/content/article/PII:S1525730412001398?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525730412001398?httpAccept=text/plain
The Lancet10.1016/s0140-6736(14)60845-x20143849944665-673Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trialEdward B Garon, Tudor-Eliade Ciuleanu, Oscar Arrieta, Kumar Prabhash, Konstantinos N Syrigos, Tuncay Goksel, Keunchil Park, Vera Gorbunova, Ruben Dario Kowalyszyn, Joanna Pikiel, Grzegorz Czyzewicz, Sergey V Orlov, Conrad R Lewanski, Michael Thomas, Paolo Bidoli, Shaker Dakhil, Steven Gans, Joo-Hang Kim, Alexandru Grigorescu, Nina Karaseva, Martin Reck, Federico Cappuzzo, Ekaterine Alexandris, Andreas Sashegyi, Sergey Yurasov, Maurice Pérolhttps://api.elsevier.com/content/article/PII:S014067361460845X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S014067361460845X?httpAccept=text/plain
Lung Cancer10.1016/j.lungcan.2016.07.019201699186-193A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapyKiyotaka Yoh, Yukio Hosomi, Kazuo Kasahara, Kazuhiko Yamada, Toshiaki Takahashi, Nobuyuki Yamamoto, Makoto Nishio, Yuichiro Ohe, Toshiko Koue, Takashi Nakamura, Sotaro Enatsu, Pablo Lee, David Ferry, Tomohide Tamura, Kazuhiko Nakagawahttps://api.elsevier.com/content/article/PII:S0169500216304172?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500216304172?httpAccept=text/plain
Annals of Oncology10.1093/annonc/mdx091.040201728ii43Subgroup analysis of adenocarcinoma patients refractory to first-line chemotherapy from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non–small cell lung cancer (NSCLC)M. Reck, L. Paz-Ares, D. Moro-Sibilot, F.A. Shepherd, F. Cappuzzo, K.B. Winfree, E. Alexandris, A. Sashegyi, R. Varea, M. Pérolhttps://api.elsevier.com/content/article/PII:S0923753419336142?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419336142?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/28/suppl_2/mdx091.040/16721670/mdx091.040.pdf
Annals of Oncology10.1093/annonc/mdx426.002201728vi54-vi55Subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase 3 study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC)M. Reck, L. Paz-Ares, M. Pérol, M. Johnson, N. Pennell, S. Novello, F. Cappuzzo, P. Bidoli, A. Zimmermann, P. Lee, A. Sashegyi, R. Varea Menendezhttps://api.elsevier.com/content/article/PII:S0923753420348390?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753420348390?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/28/suppl_6/mdx426.002/21490671/mdx426.002.pdf
ESMO Open10.1136/esmoopen-2019-000567202051e000567Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapyEdward B. Garon, Giorgio Vittorio Scagliotti, Oliver Gautschi, Martin Reck, Michael Thomas, Lara Iglesias Docampo, Haralabos Kalofonos, Joo-Hang Kim, Steven Gans, Oddrje Te Brustugun, Sergey V. Orlov, Gebra Cuyun Carter, Annamaria H. Zimmermann, Ana B. Oton, Ekaterine Alexandris, Pablo Lee, Katharina Wolff, Victoria Jennifer Stefaniak, Mark A. Socinski, Maurice Pérolhttps://api.elsevier.com/content/article/PII:S205970292030003X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S205970292030003X?httpAccept=text/plain, https://syndication.highwire.org/content/doi/10.1136/esmoopen-2019-000567
European Journal of Cancer10.1016/s0959-8049(16)31714-2201551S6213073 Exploratory analysis of frontline therapies in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) versus DOC for the treatment of stage IV non-small-cell lung cancer (NSCLC) after disease progression on platinum-based therapyE.B. Garon, G.V. Scagliotti, O. Gautschi, M. Reck, M. Thomas, L.I. Docampo, H. Kalofonos, J.H. Kim, S. Gans, O.T. Brustugun, S.V. Orlov, D. Ferry, A. Melemed, G.C. Carter, A.H. Zimmermann, J.A. Treat, E. Alexandris, P. Lee, M.A. Socinski, M. Perolhttps://api.elsevier.com/content/article/PII:S0959804916317142?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0959804916317142?httpAccept=text/plain
Annals of Oncology10.1093/annonc/mdx670.001201728x122Ramucirumab in East Asian patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy: A pooled analysis of two randomized double-blind studiesJ-Y Shih, K. Yoh, Y. Hosomi, G-C Chang, T-C Hsia, T. Tamura, R. Varea, T. Nakamura, J. Gallo, R. Cheng, S. Enatsu, K. Nakagawahttps://api.elsevier.com/content/article/PII:S0923753419563803?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419563803?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/28/suppl_10/mdx670.001/21936873/mdx670.001.pdf
Annals of Oncology10.1093/annonc/mdv343.04201526vi74Update of REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line (2L) treatment of stage IV non-small cell lung cancer (NSCLC) including subgroup analysis of histologyP. Bidoli, F. Cappuzzo, A. Favaretto, O. Alabiso, M. Tiseo, A. Chella, V. Gebbia, L. Pizzuti, L. Paz-Ares, M. Perol, E. Garon, P. Lee, A. Zimmermann, G. Cuyun Carter, M.R. Migliorinohttps://api.elsevier.com/content/article/PII:S0923753419534330?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419534330?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/26/suppl_6/vi/6681613/mdv343.04.pdf